1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,150 | 1,190 | 22:58 | |
| 1,160 | 1,210 | 22:02 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21:46 | MAXCYTE, INC. - 8-K, Current Report | - | SEC Filings | ||
| 14:24 | MaxCyte sees Q4 core revenue between $6.6M and $6.7M | 1 | Seeking Alpha | ||
| 14:12 | MaxCyte, Inc: MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results | 37 | GlobeNewswire (Europe) | ROCKVILLE, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery... ► Artikel lesen | |
| 19.11.25 | MaxCyte stellt auf Stephens-Konferenz Neuausrichtung | 1 | Investing.com Deutsch | ||
| 13.11.25 | MAXCYTE, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 13.11.25 | MaxCyte reports Q3 results | 1 | Seeking Alpha | ||
| MAXCYTE Aktie jetzt für 0€ handeln | |||||
| 13.11.25 | MaxCyte outlines $17M-$19M annualized savings through restructuring while reiterating SPL revenue guidance | 2 | Seeking Alpha | ||
| 12.11.25 | MaxCyte CFO to step down in first half of 2026 | 2 | Seeking Alpha | ||
| 12.11.25 | MaxCyte CFO Douglas Swirsky to step down in first half of 2026 | 4 | Investing.com | ||
| 12.11.25 | MaxCyte, Inc: MaxCyte Announces Planned CFO Transition in 2026 | 107 | GlobeNewswire (Europe) | ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development... ► Artikel lesen | |
| 11.11.25 | Insights into MaxCyte's Upcoming Earnings | 1 | Benzinga.com | ||
| 05.11.25 | MAXCYTE, INC. - 8-K, Current Report | - | SEC Filings | ||
| 05.11.25 | MaxCyte reports Q3 results | 1 | Seeking Alpha | ||
| 05.11.25 | MaxCyte, Inc: MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance | 173 | GlobeNewswire (Europe) | MaxCyte will now host its earnings conference call on November 12, 2025 Management will present at the Stifel Healthcare Conference on November 11, 2025 and Stephens Investment Conference on November... ► Artikel lesen | |
| 08.10.25 | MaxCyte, Inc: MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 | 3 | GlobeNewswire (USA) | ||
| 06.10.25 | MaxCyte, Inc: MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors | 310 | GlobeNewswire (Europe) | ROCKVILLE, Md., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and... ► Artikel lesen | |
| 22.09.25 | MaxCyte announces 34% workforce reduction to cut costs | 1 | Seeking Alpha | ||
| 22.09.25 | MAXCYTE, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.09.25 | MaxCyte, Inc: MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability | 235 | GlobeNewswire (Europe) | ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development... ► Artikel lesen | |
| 26.08.25 | MAXCYTE, INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CO.DON | 0,021 | -18,00 % | EQS-PVR: CO.DON AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: CO.DON AG
CO.DON AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
07.01.2026 / 12:38 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,386 | +0,65 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease | STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| IMMATICS | 7,700 | -2,35 % | Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress | IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor... ► Artikel lesen | |
| ALDEYRA | 3,369 | -4,75 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced... ► Artikel lesen | |
| MEDIFAST | 9,952 | +1,43 % | Medifast Shifts to Metabolic Health: A Durable Growth Path? | ||
| PHARMING | 1,599 | -0,31 % | Pharming Group N.V.: Pharming Group reports preliminary 2025 revenues and announces Investor Day | Leiden, The Netherlands, January 8, 2026: Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced its preliminary, unaudited revenues for the full... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,363 | -6,45 % | Coherus BioSciences: Aktie legt nach Veröffentlichung von Daten zu CCR8-Antikörper zu | ||
| ORUKA THERAPEUTICS | 25,800 | +7,50 % | Oruka meldet positive Studiendaten für ORKA-002 und stellt halbjährliche Dosierung in Aussicht | ||
| INNOVIVA | 16,800 | 0,00 % | FDA Approves Innoviva's NUZOLVENCE, First-in-Class Oral Treatment For Gonorrhea | ||
| ARMATA PHARMACEUTICALS | 5,650 | -6,61 % | Jones Trading startet Coverage für Armata Pharmaceuticals mit Kaufempfehlung und hohem Kursziel | ||
| DBV TECHNOLOGIES | 3,130 | +4,68 % | DBV Technologies S.A.: Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF | AMF Regulated InformationChâtillon, France, January 7, 2026
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
DBV Technologies (Euronext: DBV - ISIN: FR0010417345... ► Artikel lesen | |
| BRAINSTORM CELL THERAPEUTICS | 0,673 | -100,00 % | BRAINSTORM CELL THERAPEUTICS INC. - 8-K, Current Report | ||
| LIQUIDIA | 31,200 | +1,17 % | Liquidia Technologies, Inc.: Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update | Estimated YUTREPIA net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025Received more than 2,800 unique patient prescriptions since launch in... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 6,590 | -0,30 % | SIGA Technologies - Fundamentals intact amid several moving parts | Q325 was a quieter quarter for SIGA following strong Q2 sales, although this was not unexpected given its contract-driven model and inherent revenue lumpiness. No product sales were recorded, with total... ► Artikel lesen | |
| SYNDAX PHARMACEUTICALS | 17,900 | -1,10 % | Syndax Pharmaceuticals, Inc.: Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj (revumenib) Outside the U.S. |
Das Unternehmen MAXCYTE INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,050 (+4,03 %) liegt der Kurs bei 1,290 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAXCYTE INC finden Sie auf Wallstreet Online.